Asana BioSciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel targeted therapies in inflammation/immunology and oncology. Asana’s proprietary portfolio comprises multiple drug candidates, both small molecules and biologics. Our lead asset, ASN002, is an oral dual JAK/SYK inhibitor in Phase 2b clinical development for patients with moderate to severe atopic dermatitis and ha...
Asana BioSciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel targeted therapies in inflammation/immunology and oncology. Asana’s proprietary portfolio comprises multiple drug candidates, both small molecules and biologics. Our lead asset, ASN002, is an oral dual JAK/SYK inhibitor in Phase 2b clinical development for patients with moderate to severe atopic dermatitis and has broad development potential in other immunological diseases. Our oncology leads are targeted therapies in early clinical development for patients with advanced or metastatic cancers, including melanoma.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.